NO20061246L - Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse - Google Patents

Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse

Info

Publication number
NO20061246L
NO20061246L NO20061246A NO20061246A NO20061246L NO 20061246 L NO20061246 L NO 20061246L NO 20061246 A NO20061246 A NO 20061246A NO 20061246 A NO20061246 A NO 20061246A NO 20061246 L NO20061246 L NO 20061246L
Authority
NO
Norway
Prior art keywords
salts
pyrrole
polymorphic forms
indolinone compound
substituted indolinone
Prior art date
Application number
NO20061246A
Other languages
English (en)
Norwegian (no)
Inventor
Andrei Blasko
Qingwu Jin
Qun Lu
Michael Anthony Mauragis
Dian Song
Brenda Sue Vonderwell
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20061246L publication Critical patent/NO20061246L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20061246A 2003-10-02 2006-03-17 Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse NO20061246L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50810403P 2003-10-02 2003-10-02
PCT/IB2004/003070 WO2005033098A1 (en) 2003-10-02 2004-09-20 Salts and polymorphs of a pyrrole-substituted indolinone compound

Publications (1)

Publication Number Publication Date
NO20061246L true NO20061246L (no) 2006-03-29

Family

ID=34421700

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061246A NO20061246L (no) 2003-10-02 2006-03-17 Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse

Country Status (26)

Country Link
US (1) US7247627B2 (xx)
EP (1) EP1670785B1 (xx)
JP (1) JP4933259B2 (xx)
KR (2) KR20080007520A (xx)
CN (1) CN100432072C (xx)
AR (1) AR047762A1 (xx)
AT (1) ATE473223T1 (xx)
AU (1) AU2004277464B2 (xx)
BR (1) BRPI0415022A (xx)
CA (1) CA2540639C (xx)
CY (1) CY1110771T1 (xx)
DE (1) DE602004028028D1 (xx)
DK (1) DK1670785T3 (xx)
ES (1) ES2348623T3 (xx)
HK (1) HK1093068A1 (xx)
IL (1) IL174414A (xx)
MX (1) MXPA06003661A (xx)
NO (1) NO20061246L (xx)
NZ (1) NZ546001A (xx)
PL (1) PL1670785T3 (xx)
PT (1) PT1670785E (xx)
RU (1) RU2319702C2 (xx)
SI (1) SI1670785T1 (xx)
TW (1) TW200524921A (xx)
WO (1) WO2005033098A1 (xx)
ZA (1) ZA200602691B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
AU2006227880A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
CA2622870A1 (en) * 2005-09-20 2007-03-29 Pfizer Products Inc. Dosage forms and methods of treatment using a tyrosine kinase inhibitor
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
KR101428833B1 (ko) * 2007-04-04 2014-08-08 오츠카 가가쿠 가부시키가이샤 티탄산칼륨, 그의 제조 방법, 마찰재 및 수지 조성물
BRPI0918629B8 (pt) * 2008-09-17 2021-05-25 Novartis Ag sal de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1-1'-bifenil]-3-carboxamida, e composição farmacêutica
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9851313B2 (en) * 2015-03-03 2017-12-26 Panalytical B.V. Quantitative X-ray analysis—ratio correction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CN1329390C (zh) * 2000-02-15 2007-08-01 苏根公司 吡咯取代的2-二氢吲哚酮蛋白激酶抑制剂
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
ES2453164T3 (es) * 2001-08-15 2014-04-04 Pharmacia & Upjohn Company Llc Cristales que incluyen una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, procedimientos para su preparación y sus composiciones
YU67702A (sh) 2001-09-28 2004-12-31 Pfizer Products Inc. Postupak za dobijanje alkansulfonil piridina
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
CN1308326C (zh) * 2002-02-15 2007-04-04 法马西亚和厄普乔恩公司 吲哚满酮衍生物的制备方法
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona

Also Published As

Publication number Publication date
US7247627B2 (en) 2007-07-24
EP1670785B1 (en) 2010-07-07
DE602004028028D1 (de) 2010-08-19
JP2007507482A (ja) 2007-03-29
MXPA06003661A (es) 2006-06-05
PT1670785E (pt) 2010-09-16
RU2319702C2 (ru) 2008-03-20
CN1863796A (zh) 2006-11-15
HK1093068A1 (en) 2007-02-23
CY1110771T1 (el) 2015-06-10
ATE473223T1 (de) 2010-07-15
CN100432072C (zh) 2008-11-12
RU2006110541A (ru) 2006-08-27
ZA200602691B (en) 2007-06-27
WO2005033098A1 (en) 2005-04-14
US20050118255A1 (en) 2005-06-02
KR20080007520A (ko) 2008-01-21
NZ546001A (en) 2009-09-25
BRPI0415022A (pt) 2006-11-28
IL174414A (en) 2011-12-29
PL1670785T3 (pl) 2010-12-31
WO2005033098A8 (en) 2006-04-20
SI1670785T1 (sl) 2010-10-29
KR20060058728A (ko) 2006-05-30
ES2348623T3 (es) 2010-12-09
WO2005033098A9 (en) 2006-05-26
EP1670785A1 (en) 2006-06-21
JP4933259B2 (ja) 2012-05-16
AR047762A1 (es) 2006-02-22
AU2004277464B2 (en) 2010-07-08
AU2004277464A1 (en) 2005-04-14
IL174414A0 (en) 2008-02-09
TW200524921A (en) 2005-08-01
DK1670785T3 (da) 2010-10-18
CA2540639C (en) 2010-08-31
CA2540639A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
NO20061246L (no) Salter og polymorfe former av en pyrrol-substituert indolinonforbindelse
NO2019005I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter
NO20071290L (no) Enantiomert rene aminoheteroarylforbindelser som protein kinase inhibitorer
GB2431927A9 (en) 1,2-Disubstituted indoles & derivatives thereof astherapeutic 5-iipoxygenase-activating protein (fl ap) inhibitors
UA107175C2 (uk) Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
RS54607B1 (en) 5-SUBSTITUATED HINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
EA200801381A1 (ru) Производные пиримидина
AU2003247522A1 (en) Methods for synthesis of acyloxyalkyl derivatives of gaba analogs
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
PL368317A1 (en) Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
ATE433968T1 (de) Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
PT1713801E (pt) Processo para a preparação de 1-(2s,3s)-2-benzidril-n-(5- -terc-butil-2-metoxibenzil)-quinuclidina-3-amina
EA200970041A1 (ru) Ингибиторы акт (протеинкиназы в)
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
EA200970604A1 (ru) Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
EP1628974A4 (en) HYDANTOIN DERIVATIVES AS INHIBITORS OF THE TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE)
NO20060191L (no) 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)2,2-difenylacetamidderivater som muskarinreceptoragonister
EA200600330A1 (ru) Замещённые имидазопиримидины для предупреждения и лечения рака
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
ATE405588T1 (de) Analoge des somatostatin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application